top of page
"From the beginning our interests have been aligned."
Venkat Reddy, PhD
"We brought together a world class team."
Rajiv and Venkat had been tracking the emergence of a new class of therapeutics called PROTAC for several years. They saw scientific as well as the business development traction with big pharma and spent a lot of time thinking about how best to enter the field. While other companies were going after cancer and CNS indications, Rajiv and Venkat saw that cardiovascular disease was underexplored with PROTACs. They believed that the nature of the modality would provide a unique opportunity in cardiovascular diseases where they had specific expertise. Together, they built the company to solve a marketplace problem.
bottom of page